Pneumococcal Conjugate Vaccine (7-Valent)
- Atc Codes:J07AL
Table of contents
- Brand Names
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
Brand Names
Europe
Austria: Prevnar; Belgium: Pneumo 23, Prevenar; Czech Republic: Pneumo 23, Prevenar, Synflorix; Estonia: Pneumo 23, Prevenar, Synflorix; Finland: Pneumovax, Prevenar, Synflorix; France: Prevenar, Prevnar, Synflorix; Germany: Prevenar, Synflorix; Greece: Pneumovax 23, Pnu Imune, Prevenar, Synflorix; Hungary: Prevenar; Ireland: Pneumovax, Prevenar, Synflorix; Italy: Prevenar, Synflorix; Latvia: Prevenar; Lithuania: Pneumo 23, Prevenar, Synflorix; Malta: Prevenar; Netherlands: Pneumo 23, Prevenar, Synflorix; Poland: Pneumovax 23, Prevenar, Synflorix; Portugal: Pneumo 23, Penumovax 23, Prevenar, Synflorix; Romania: Pneumo 23, Prevenar, Synflorix; Slovakia: Pneumo 23, Prevenar, Synflorix; Slovenia: Prevenar; Spain: Pneumo 23; Sweden: Pneumo 23, Pneumovax, Prevenar, Synflorix; UK: Prevenar, Synflorix.
North America
Canada: Pneumo 23, Pneumovax 23, Prevnar, Synflorix.
Latin America
Argentina: Prevenar; Brazil: Vacina Pneumocócica Conjugada 7-Valente; Mexico: Prevenar.
Asia
Japan: Pneumovax.
Drug combinations
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Vaccines; Inactivated Bacterial Vaccine. (ATC-Code: J07AL).
Mechanism of action
Promotes active immunization against invasive disease caused by S. pneumoniae capsular serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, all of which are individually conjugated to CRM197 protein.
Therapeutic use
Immunization of infants and toddlers against Streptococcus pneumoniae infection, or otitis media, caused by serotypes included in vaccine.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid.
Warnings and precautions
Anaphylactoid/hypersensitivity reactions might occur. Immunization should be delayed during the course of acute severe febrile illness. May be administered in acute illness (with or without fever). Use of pneumococcal conjugate vaccine does not replace use of 23-valent pneumococcal polysaccharide vaccine in children ≥24 months of age with asplenia, chronic illness, HIV infection, sickle cell disease, or who are immunocompromised. Use with caution in history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy (bleeding/hematoma may occur from I.M. administration). Not to be used to treat pneumococcal infections or to provide immunity against diphtheria. Febrile seizures reported (rare). Use with caution in severely immunocompromised patients (may have reduced response to vaccination). Packaging may contain natural latex rubber.